gadodiamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diagnostic agents, gadolinium derivatives	4494	131410-48-5

Description:

Molecule	Description
Synonyms: omniscan gadodiamide	for intravenous administration with MRI in adult patients for contrast enhancement of CNS lesions Molecular weight: 573.66 Formula: C16H26GdN5O8 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

omniscan
gadodiamide

for intravenous administration with MRI in adult patients for contrast enhancement of CNS lesions

Molecular weight: 573.66
Formula: C16H26GdN5O8
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	0.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.79 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.46 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 8, 1993	FDA	GE HEALTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	2250.51	48.76	349	2661	4207	63481805
Skin hypertrophy	411.79	48.76	79	2931	3312	63482700
Skin induration	409.52	48.76	78	2932	3145	63482867
Skin tightness	310.37	48.76	65	2945	4251	63481761
Skin fibrosis	214.41	48.76	37	2973	843	63485169
Fibrosis	199.54	48.76	45	2965	4147	63481865
Skin hyperpigmentation	153.96	48.76	39	2971	5882	63480130
Joint contracture	129.81	48.76	27	2983	1697	63484315
Joint range of motion decreased	129.54	48.76	51	2959	32377	63453635
Scar	105.18	48.76	35	2975	13747	63472265
Emotional distress	95.27	48.76	41	2969	32508	63453504
Skin discolouration	92.51	48.76	42	2968	37786	63448226
Anhedonia	80.27	48.76	27	2983	10947	63475065
Peau d'orange	77.20	48.76	12	2998	138	63485874
Oedema peripheral	73.14	48.76	65	2945	189446	63296566
Erythema	71.25	48.76	62	2948	175689	63310323
Joint stiffness	70.50	48.76	36	2974	41833	63444179
Mobility decreased	64.26	48.76	50	2960	121109	63364903
Skin plaque	62.94	48.76	21	2989	8299	63477713
Extremity contracture	62.21	48.76	14	2996	1271	63484741
Muscle contracture	60.91	48.76	14	2996	1397	63484615
Pain	60.07	48.76	117	2893	740511	62745501
Deformity	59.63	48.76	22	2988	11662	63474350
Magnetic resonance imaging head abnormal	55.97	48.76	14	2996	1999	63484013
Contrast media deposition	54.79	48.76	8	3002	58	63485954

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	2332.22	47.16	387	2811	3618	34950115
Skin hypertrophy	385.81	47.16	80	3118	2549	34951184
Skin induration	365.86	47.16	74	3124	2077	34951656
Skin tightness	362.44	47.16	74	3124	2179	34951554
Joint contracture	243.41	47.16	52	3146	1909	34951824
Joint range of motion decreased	243.02	47.16	67	3131	7245	34946488
Skin fibrosis	225.90	47.16	44	3154	1008	34952725
Fibrosis	182.07	47.16	43	3155	2493	34951240
Scar	167.96	47.16	48	3150	5896	34947837
Extremity contracture	132.91	47.16	27	3171	769	34952964
Deformity	130.50	47.16	30	3168	1542	34952191
Emotional distress	127.84	47.16	49	3149	14977	34938756
Mobility decreased	121.94	47.16	58	3140	30070	34923663
Joint stiffness	112.72	47.16	41	3157	10832	34942901
Anhedonia	107.05	47.16	36	3162	7549	34946184
Pain	87.31	47.16	100	3098	204575	34749158
Oedema peripheral	86.74	47.16	78	3120	119734	34833999
Injury	84.16	47.16	40	3158	20647	34933086
Skin discolouration	71.03	47.16	34	3164	17811	34935922
Skin disorder	70.16	47.16	31	3167	13524	34940209
Musculoskeletal stiffness	65.50	47.16	45	3153	46635	34907098
Skin hyperpigmentation	64.45	47.16	20	3178	3244	34950489
Anxiety	55.22	47.16	56	3142	99372	34854361
Gait inability	49.35	47.16	28	3170	20730	34933003
Peau d'orange	49.28	47.16	9	3189	143	34953590
Muscle contracture	48.74	47.16	13	3185	1231	34952502

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nephrogenic systemic fibrosis	3162.99	54.84	504	4269	5656	79733959
Skin hypertrophy	627.02	54.84	124	4649	4804	79734811
Skin induration	600.81	54.84	118	4655	4407	79735208
Skin tightness	536.27	54.84	111	4662	5411	79734204
Skin fibrosis	342.84	54.84	62	4711	1462	79738153
Joint contracture	293.60	54.84	59	4714	2465	79737150
Joint range of motion decreased	267.31	54.84	93	4680	33189	79706426
Fibrosis	244.67	54.84	58	4715	5251	79734364
Scar	196.84	54.84	61	4712	15135	79724480
Biopsy brain abnormal	176.47	54.84	21	4752	8	79739607
Skin hyperpigmentation	173.52	54.84	47	4726	7256	79732359
Oedema peripheral	140.83	54.84	118	4655	252170	79487445
Joint stiffness	138.06	54.84	61	4712	40769	79698846
Skin discolouration	134.55	54.84	60	4713	40974	79698641
Emotional distress	132.84	54.84	59	4714	39910	79699705
Anhedonia	124.74	54.84	43	4730	14855	79724760
Mobility decreased	119.26	54.84	80	4693	122095	79617520
Extremity contracture	117.82	54.84	26	4747	1706	79737909
Deformity	113.64	54.84	36	4737	9569	79730046
Peau d'orange	103.92	54.84	18	4755	327	79739288
Skin disorder	99.75	54.84	46	4727	33897	79705718
Pain	93.08	54.84	157	4616	703645	79035970
Erythema	88.03	54.84	86	4687	223204	79516411
Muscle contracture	84.61	54.84	21	4752	2296	79737319
Skin plaque	82.18	54.84	29	4744	10716	79728899
Injury	69.00	54.84	48	4725	77448	79662167
Musculoskeletal stiffness	68.14	54.84	67	4706	174941	79564674
Magnetic resonance imaging head abnormal	66.86	54.84	18	4755	2708	79736907
Skin exfoliation	63.26	54.84	40	4733	55060	79684555
Pruritus	62.79	54.84	96	4677	394552	79345063
Muscle tightness	62.75	54.84	25	4748	12889	79726726
Anxiety	59.97	54.84	74	4699	248438	79491177
Magnetic resonance imaging abnormal	58.17	54.84	17	4756	3442	79736173
Gait disturbance	56.97	54.84	66	4707	207440	79532175
Muscular weakness	56.07	54.84	58	4715	160671	79578944

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V08CA03	VARIOUS CONTRAST MEDIA MAGNETIC RESONANCE IMAGING CONTRAST MEDIA Paramagnetic contrast media
MeSH PA	D003287	Contrast Media
MeSH PA	D064907	Diagnostic Uses of Chemicals
FDA MoA	N0000175862	Magnetic Resonance Contrast Activity
FDA EPC	N0000180184	Paramagnetic Contrast Agent

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Magnetic resonance imaging	indication	113091000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D04284	KEGG_DRUG
4020689	VUID
N0000148302	NUI
4020689	VANDF
CHEBI:31642	CHEBI
CHEMBL1200346	ChEMBL_ID
C064925	MESH_SUPPLEMENTAL_RECORD_UI
6636	INN_ID
DB00225	DRUGBANK_ID
84F6U3J2R6	UNII
41144	RXNORM
10205	MMSL
4771	MMSL
d04083	MMSL
004259	NDDF
354088005	SNOMEDCT_US
396067007	SNOMEDCT_US
C0082646	UMLSCUI
153921	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
OMNISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0407-0690	INJECTION	287 mg	INTRAVENOUS	NDA	28 sections
OMNISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0407-0690	INJECTION	287 mg	INTRAVENOUS	NDA	28 sections
OMNISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0407-0690	INJECTION	287 mg	INTRAVENOUS	NDA	28 sections
OMNISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0407-0690	INJECTION	287 mg	INTRAVENOUS	NDA	28 sections
OMNISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0407-0690	INJECTION	287 mg	INTRAVENOUS	NDA	28 sections
OMNISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0407-0690	INJECTION	287 mg	INTRAVENOUS	NDA	28 sections
OMNISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0407-0691	INJECTION	287 mg	INTRAVENOUS	NDA	28 sections
OMNISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0407-0691	INJECTION	287 mg	INTRAVENOUS	NDA	28 sections